Replimune Group's melanoma drug Tudriqev received accelerated FDA approval after two prior rejections, based on a 24.20% response rate in trials. Following this, BMO Capital raised its price target for Replimune stock from $16 to $20, indicating strong growth potential. However, the company is under investigation by Pomerantz LLP for possible unlawful business practices related to its clinical data submissions. Investors should watch how this legal scrutiny unfolds alongside the drug's market launch.
Berkshire Hathaway will release its Q2 2026 earnings on August 8, with analysts expecting earnings of $5.04 per share and revenue of $96.52 billion. The company has been actively buying back up to $11 billion of its own shares, signaling management's...
Klépierre, a leading European shopping mall operator, announced it has 286,861,172 shares and nearly the same number of exercisable voting rights as of July 31, 2026. The company's portfolio is valued at €21.8 billion, comprising large shopping cente...
Klépierre, a leading European shopping center operator, disclosed its total number of shares and voting rights as of July 31, 2026. The company has 286,861,172 shares and 286,793,348 exercisable voting rights. Klépierre's portfolio is valued at €21.8...
Credit Agricole S.A. announced the publication of its 2026 half-year financial report via an amendment to its 2025 Universal Registration Document, filed with the French financial regulator AMF on August 7, 2026. The report is publicly accessible on ...
Scotiabank increased its price target for BCE Inc. to C$40 and maintained an "Outperform" rating following BCE's strong Q2 2026 results. The company reported adjusted earnings of C$0.65 per share, a 3.2% year-over-year increase, and total revenues ro...
